Literature DB >> 22607644

Probable etoposide interaction with Echinacea.

John B Bossaer1, Brian L Odle.   

Abstract

Echinacea is an herbal supplement commonly used as an immune system stimulant to prevent infections, such as the common cold or flu. Echinacea has been documented as a cyctochrome P450 (CYP) 3A4 inhibitor in vitro, but no formal studies have been conducted in humans. Etoposide is a cytotoxic, topoisomerase II inhibitor, chemotherapeutic agent used in the treatment of lung cancer. Etoposide is primarily metabolized by CYP 3A4. We report the first possible drug-herbal interaction between Echinacea and etoposide. A 61-year-old gentleman newly diagnosed with nonsmall cell lung cancer began concurrent chemoradiation with cisplatin and etoposide. He was admitted to the hospital on day 8 of his first cycle and found to be thrombocytopenic. His platelet count eventually reached a nadir of 16 × 10(3)/L, requiring platelet transfusion support. Upon admission, it was discovered he was taking Echinacea, which was discontinued. He received his next cycle of chemotherapy without taking Echinacea. His platelet count decreased to a nadir of 44 × 10(3)/L, but he did not require platelet transfusions. Echinacea likely contributed to this patient's profound thrombocytopenia and should be avoided in patients receiving etoposide and possibly other chemotherapeutic drugs that are CYP 3A4 substrates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607644     DOI: 10.3109/19390211.2012.682643

Source DB:  PubMed          Journal:  J Diet Suppl        ISSN: 1939-0211


  8 in total

Review 1.  Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

Review 2.  Critical evaluation of causality assessment of herb-drug interactions in patients.

Authors:  Charles Awortwe; Memela Makiwane; Helmuth Reuter; Christo Muller; Johan Louw; Bernd Rosenkranz
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

3.  Patient-centered care in lung cancer: exploring the next milestones.

Authors:  Eran Ben-Arye; Noah Samuels
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 4.  Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.

Authors:  Roberto Collado-Borrell; Vicente Escudero-Vilaplana; Rosa Romero-Jiménez; Irene Iglesias-Peinado; Ana Herranz-Alonso; María Sanjurjo-Sáez
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-17       Impact factor: 4.553

5.  In Vitro Assessment of the Interaction Potential of Ocimum basilicum (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism.

Authors:  Saneesh Kumar; Patrick J Bouic; Bernd Rosenkranz
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 6.  Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings.

Authors:  Pius S Fasinu; Gloria K Rapp
Journal:  Front Oncol       Date:  2019-12-03       Impact factor: 6.244

7.  Proliferative activity of a blend of Echinacea angustifolia and Echinacea purpurea root extracts in human vein epithelial, HeLa, and QBC-939 cell lines, but not in Beas-2b cell lines.

Authors:  Simon Angelo Cichello; Qian Yao; Xiao Qiong He
Journal:  J Tradit Complement Med       Date:  2015-03-11

Review 8.  Herb-Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements.

Authors:  Annemarie Lippert; Bertold Renner
Journal:  J Clin Med       Date:  2022-03-12       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.